Exercise for triple-negative breast cancer patients
Part of Cancer, Skin clinical trials.
This trial tests whether a structured exercise program can help women with newly diagnosed triple-negative breast cancer who are getting a specific combination of immunotherapy and chemotherapy. The goal is to see if staying active during treatment improves outcomes and well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 65 years old.
- You have been newly diagnosed with triple-negative breast cancer (stages I to III).
- You are scheduled to receive a treatment that includes both immunotherapy (pembrolizumab) and a type of chemotherapy called anthracycline-based.
- You do not have an unstable heart condition (like worsening coronary artery disease, heart failure, or dangerous heart rhythm problems).
- You do not have any bone or joint problem that would prevent you from exercising.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if aerobic exercise can help women and men with stage 2 or 3 triple-negative breast cancer who are getting chemotherapy and immunotherapy before surgery. It aims to see if exercise improves treatment outcomes and quality of life.
This trial tests whether a supervised exercise program can help women with triple-negative breast cancer who are receiving chemotherapy. It may help manage side effects and improve well-being during treatment.
This trial looks at whether a structured physical exercise program during neoadjuvant chemotherapy can help women with triple-negative breast cancer. You may qualify if you are treated at the specific hospital in Madrid and your tumor matches the required type and size.
This study tests whether a healthy lifestyle program (diet and exercise) can help improve the results of breast cancer treatment before surgery. It's for women with triple-negative breast cancer who are getting chemotherapy and immunotherapy.
This trial tests whether a structured lifestyle program (diet and exercise) can make standard chemotherapy before surgery work better for triple-negative breast cancer. It looks at how the program affects your body’s response to treatment and your overall health.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
Hear when a new Cancer, Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.